Conduit Pharmaceuticals (CDT) Stock Overview
A clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
CDT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Conduit Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.68 |
| 52 Week High | US$4,680.00 |
| 52 Week Low | US$2.45 |
| Beta | 0 |
| 1 Month Change | -64.44% |
| 3 Month Change | -83.76% |
| 1 Year Change | -99.94% |
| 3 Year Change | -99.98% |
| 5 Year Change | n/a |
| Change since IPO | -99.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| CDT | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -27.4% | 2.1% | 1.4% |
| 1Y | -99.9% | -27.6% | 11.6% |
Return vs Industry: CDT underperformed the US Life Sciences industry which returned -27.5% over the past year.
Return vs Market: CDT underperformed the US Market which returned 12.6% over the past year.
Price Volatility
| CDT volatility | |
|---|---|
| CDT Average Weekly Movement | 27.6% |
| Life Sciences Industry Average Movement | 11.2% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: CDT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CDT's weekly volatility (28%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 6 | Andrew Regan | www.conduitpharma.com |
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It has strategic services agreement with formulation development CDMO Agility Life Sciences to develop new solid oral-dosage form products.
Conduit Pharmaceuticals Inc. Fundamentals Summary
| CDT fundamental statistics | |
|---|---|
| Market cap | US$2.58m |
| Earnings (TTM) | -US$19.40m |
| Revenue (TTM) | n/a |
Is CDT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CDT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$19.40m |
| Earnings | -US$19.40m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -24.32 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 99.1% |
How did CDT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/04 13:20 |
| End of Day Share Price | 2025/06/04 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Conduit Pharmaceuticals Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.